Huadong Medicine Co., Ltd. (000963.SZ) has announced that on November 17, 2026, its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Zhongmei Huadong") received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), granting approval for the clinical trial application of HDM4002 Injection filed by Zhongmei Huadong. This drug is intended for the treatment of adult patients with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression, in order to reduce the loss of kidney function. This approval represents an important milestone in the product's research and development process and will further enhance the company's core competitiveness in the field of autoimmune therapy.
Comments